Atea Corp (AVIR) - מקדם חוב לטווח ארוך להון

The manufacturer's dependence on Asian raw material supplies and geopolitical complexities during drug trials coexist with the implementation of ESG waste disposal standards and cold chain optimization. This chart of the market value demonstrates the 0.00 indicator. Atea Pharmaceuticals (AVIR) is currently actively developing its hepatitis C portfolio, creating innovative therapy methods within the framework of ongoing clinical trials.

An investment audit of Atea Pharmaceuticals (AVIR) requires an assessment of financial leverage via the ratio of liabilities with a maturity of over one year to equity. This metric measures the company's reliance on debt financing, which is critical for Atea Pharmaceuticals, as it has minimized capital expenditures by utilizing external CDMO facilities, a factor reflected in the long-term debt-to-equity trend.